Abstract Library

#3557 Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,

#3546 Neuroendocrine tumors, experience at Instituto Nacional de Enfermedades Neoplasicas in a hospital from Peru

Introduction: Neuroendocrine tumors (NETs) are very rare cancers with indolent behavior, diagnosis is a challenge because of inespecific symptoms, treatments are in development and prognosis is variable.

Conference:

Presenting Author: Paitan V

Authors: Paitan V, Leonardo A, Bravo J, Taxa L, Castro V,

Keywords: Neuroendocrine tumor, Incidence, survival,

#3519 Neuroendocrine neoplasms of gall bladder, Peruvian experience

Introduction: Neuroendocrine neoplasms of the gall bladder (GB) are rare tumors classified as neuroendocrine tumor (NET), neuroendocrine carcinoma (NEC), and mixed adeno-neuroendocrine carcinoma (MANEC).

Conference:

Presenting Author: Paitan V

Authors: Paitan V, Bravo J, Leonardo A, Taxa L, Ruiz E,

Keywords: Neuroendocrine carcinoma, Gallbladder, Neuroendocrine Neoplasm,

#3272 Carcinoid heart disease in Chilean NET patients with malignant carcinoid syndrome: Long-term cohort from a developing country

Introduction: Carcinoid heart disease (CHD) is an important cause of morbidity in patients with Neuroendocrine Tumors (NET) and could be associated with poorer prognosis. There is scarce data about CHD in low and middle-income countries, and its impact has not been studied in Latin American patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Carrillo D

Authors: Carrillo D, Muñoz-Medel M, Pinto M, Retamal I, Bravo L,

Keywords: carcinoid heart disease, carcinoid syndrome, prognostic factors, Latin America,

#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Munoz Medel M

Authors: Munoz-Medel M, Cordova Delgado M, Pinto M, Bravo M, Retamal I,

Keywords: Neuroendocrine, Chromogranin A, Biomarker,